scholarly journals Antineoplaston A10

2020 ◽  
Author(s):  
Keyword(s):  
Antineoplaston A10

Synthesis of antineoplaston A10 analogs as potential antitumor agents

1998 ◽  
Vol 21 (2) ◽  
pp. 157-163 ◽  
Author(s):  
Bo-Gil Choi ◽  
Ok-Young Kim ◽  
Byung-Ho Chung ◽  
Won-Jea Cho ◽  
Seung-Hoon Cheon ◽  
...  
Keyword(s):  
Antitumor Agents ◽  
Antineoplaston A10 ◽  
Potential Antitumor

Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma

Drugs in R&D ◽  
2003 ◽  
Vol 4 (2) ◽  
pp. 91-101 ◽  
Author(s):  
Stanislaw R. Burzynski ◽  
Robert I. Lewy ◽  
Robert A. Weaver ◽  
Maxwell L. Axler ◽  
Tomasz J. Janicki ◽  
...  
Keyword(s):  
Brain Stem ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Brain Stem Glioma ◽  
Antineoplaston A10

Synthesis of Mannich bases of Antineoplaston A10 and their antitumor activity

1994 ◽  
Vol 17 (6) ◽  
pp. 467-469 ◽  
Author(s):  
Bo-Gil Choi ◽  
Hee-Kyoung Seo ◽  
Byung-Ho Chung ◽  
Sang-Un Choi ◽  
Chong-Ock Lee
Keyword(s):  
Antitumor Activity ◽  
Mannich Bases ◽  
Antineoplaston A10

scholarly journals Antineoplastons A10 and AS2-1 in the Treatment of Children with Optic Pathway Glioma: Final Report for Protocol BT-23

2017 ◽  
Vol 6 (1) ◽  
pp. 25
Author(s):  
Stanislaw R. Burzynski ◽  
Tomasz J. Janicki ◽  
Gregory S. Burzynski
Keyword(s):  
Progression Free Survival ◽  
Complete Response ◽  
Optic Pathway Glioma ◽  
Final Report ◽  
Optic Pathway ◽  
Length Of Treatment ◽  
Best Response ◽  
Median Dosage ◽  
Antineoplaston A10 ◽  
Grade 3

Protocol BT-23, a Phase II study, was performed to determine the efficacy and safety of combination Antineoplaston A10 and Antineoplaston AS2-1 (ANP) in children with an optic pathway glioma (OPG). Sixteen patients (12 males, 4 females) ages 1 to 16 years (median age 4.5 years) were treated. The patients received ANP, by intravenous infusion, six times daily (i.e., every four hours). The length of treatment extended from a minimum of 4.1 weeks to a maximum of 210.0 weeks. The median dosage of A10 was 8.07 g/kg/d while for AS2-1 itwas 0.39 g/kg/d.Patients’ best response to ANP was determined: 12.5% of this patient population achieved a complete response, 18.8% achieved a partial response, and 31.3% maintained stable disease. The median overall survival was 78.5 months (95% CI: 37.6-92.3) while median progression-free survival was 45.4 months (95% CI: 7.1-71.4). ANPwas associated with a12% incidence of Grade 3 and a12% incidence of Grade 4 adverse drug experiences (ADEs). There were no Grade 5 ADEs. Grade 3 ADEs included somnolence and elevated SGOT; Grade 4 ADEsincluded hypernatremia and hypokalemia. Long-term quality of life was excellent with no chronic toxicity identified. Children with an OPG respond very well to ANP with good efficacy and toxicity profiles. 

scholarly journals Antineoplastic Effect of Antineoplaston A10 to Cultured Osteosarcoma Cells.

1991 ◽  
Vol 39 (4) ◽  
pp. 1691-1694
Author(s):  
Setsuro Komiya ◽  
Kensuke Yamanaka ◽  
Seigo Kurosaki ◽  
Kazuhito Minamitani ◽  
Akio Inoue ◽  
...  
Keyword(s):  
Osteosarcoma Cells ◽  
Antineoplastic Effect ◽  
Antineoplaston A10
Sign in / Sign up

Export Citation Format

Share Document